Stock Scorecard



Stock Summary for Ocular Therapeutix Inc (OCUL) - $2.29 as of 11/28/2023 8:48:31 PM EST

Total Score

11 out of 29

Currently on the following lists
Small Cap Stock List
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for OCUL

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for OCUL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for OCUL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for OCUL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for OCUL

Ocular Therapeutix ( NASDAQ:OCUL ) Downgraded by StockNews.com to Sell 11/9/2023 9:50:00 AM
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences - Ocular Therapeutix ( NASDAQ:OCUL ) 11/8/2023 1:00:00 PM
Verve Therapeutics ( VERV ) Surges 28.0%: Is This an Indication of Further Gains? 11/1/2023 11:06:00 AM
Open-Angle Glaucoma Market Size and Share to Accelerate Substantially by 2032, Predicts DelveInsight | Key Companies in the Market - SPARC, AbbVie, Ocuphire, Santen, Glaukos, Ocular Therapeutix, VivaVision Biotech, MediPrint Ophthalmics 10/12/2023 9:01:00 PM
JMP Securities Sticks to Its Buy Rating for Crinetics Pharmaceuticals ( CRNX ) 9/10/2023 7:15:00 PM
Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference 8/9/2023 12:00:00 PM
Ocular Therapeutix ( OCUL ) Reports Q2 Loss, Tops Revenue Estimates 8/7/2023 11:15:00 PM
Karyopharm Therapeutics ( KPTI ) Reports Q2 Loss, Tops Revenue Estimates 8/2/2023 12:45:00 PM
Stevanato Group ( STVN ) Beats Q2 Earnings and Revenue Estimates 7/28/2023 1:45:00 PM
Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer Bio 7/19/2023 9:01:00 PM

Financial Details for OCUL

Company Overview

Ticker OCUL
Company Name Ocular Therapeutix Inc
Country USA
Description Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2023
Next Earnings Date N/A

Stock Price History

Last Day Price 2.29
Last Day Price Updated 11/28/2023 8:48:31 PM EST
Last Day Volume 363,144
Average Daily Volume 959,190
52-Week High 7.96
52-Week Low 2.00
Last Price to 52 Week Low 14.50 %

Valuation Measures

Trailing PE N/A
Industry PE 56.90
Sector PE 61.34
5-Year Average PE -18.92
Free Cash Flow Ratio 1.65
Industry Free Cash Flow Ratio 10.31
Sector Free Cash Flow Ratio 30.12
Current Ratio Most Recent Quarter 4.03
Total Cash Per Share 1.39
Book Value Per Share Most Recent Quarter 0.10
Price to Book Ratio 4.90
Industry Price to Book Ratio 4.85
Sector Price to Book Ratio 21.70
Price to Sales Ratio Twelve Trailing Months 4.17
Industry Price to Sales Ratio Twelve Trailing Months 104.15
Sector Price to Sales Ratio Twelve Trailing Months 28.65

Share Statistics

Total Shares Outstanding 79,419,000
Market Capitalization 181,869,510
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Dividend King? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00 %
5-Year Dividend Payments Count 0
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00 %
Annual Earnings Growth -984.05 %
Reported EPS 12 Trailing Months -1.01
Reported EPS Past Year -0.82
Reported EPS Prior Year -0.96
Net Income Twelve Trailing Months -67,058,000
Net Income Past Year -71,038,000
Net Income Prior Year -6,553,000
Quarterly Revenue Growth YOY 26.00 %
5-Year Revenue Growth 117.42 %

Balance Sheet

Total Cash Most Recent Quarter 110,550,000
Total Cash Past Year 102,300,000
Total Cash Prior Year 164,164,000
Net Cash Position Most Recent Quarter 36,661,000
Net Cash Position Past Year 48,294,000
Long Term Debt Past Year 54,006,000
Long Term Debt Prior Year 51,435,000
Total Debt Most Recent Quarter 73,889,000
Equity to Debt Ratio Past Year 0.40
Equity to Debt Ratio Most Recent Quarter 0.10
Total Stockholder Equity Past Year 35,379,000
Total Stockholder Equity Prior Year 87,999,000
Total Stockholder Equity Most Recent Quarter 7,853,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.17
MACD Signal -0.13
20-Day Bollinger Lower Band 1.73
20-Day Bollinger Middle Band 3.54
20-Day Bollinger Upper Band 5.35
Beta 1.18
RSI 39.59
50-Day SMA 4.46
200-Day SMA 7.92

System

Modified 11/28/2023 11:55:16 AM EST